$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law

GRAIL, Inc. faces a securities fraud class action lawsuit after its stock plummeted 50% on February 20, 2026, following the announcement that its NHS-Galleri cancer trial failed to meet its primary endpoint of reducing late-stage cancers. Investors allege the company misrepresented the trial's design and results, claiming the three-year timeframe was insufficient to achieve the stated objective. The lead plaintiff deadline is August 4, 2026.